Patent ID: 7615214

Claim:
A method of treating a disease in which the morbid state progresses by abnormal angiogenesis, comprising administering to a human or an animal in need of such treatment an effective amount of a recombinant monoclonal antibody selected from the group consisting of a humanized antibody and an antibody fragment thereof, said recombinant monoclonal antibody specifically binding to the human VEGF receptor Flt-1, and wherein the recombinant monoclonal antibody binds to an epitope present in a region of the 100 th to 204 th positions from the N-terminal amino acid including a signal sequence of the human VEGF receptor Flt-1, and said recombinant monoclonal antibody comprises an antibody heavy chain (H chain) variable region (V region), and an antibody light chain (L chain) variable region (V region), and wherein said H chain V region comprises the amino acid sequence of SEQ ID NO:91.